(Reuters) - In a new filing, the company said the review will "likely
extend" beyond its prior view "due to a change in the projected
timing of certain activities required for the completion of the
FDA's review."
Momenta declined to provide a new projection for the timing
but said it believes the FDA review "continues to progress
satisfactorily."
Read more at Reuters.com Government Filings News
extend" beyond its prior view "due to a change in the projected
timing of certain activities required for the completion of the
FDA's review."
Momenta declined to provide a new projection for the timing
but said it believes the FDA review "continues to progress
satisfactorily."
Read more at Reuters.com Government Filings News
No comments:
Post a Comment